FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAdaptive Biotechnologies Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ADPT
Adaptive Biotechnologies Corporation Stock AnalysisComprehensive stock analysis for Adaptive Biotechnologies Corporation (ADPT) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisADPT
ADPT
Adaptive Biotechnologies Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ADPT
  1. Home
  2. Stocks
  3. Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation

🇺🇸ADPT•NASDAQ

Adaptive Biotechnologies Corporation

🇺🇸ADPT•NASDAQ
Market cap
$4.61B

Your view on ADPT

Mkt Cap
$4.61B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Adaptive Biotechnologies Corporation

Industry
Biotechnology
Sector
Healthcare
CEO
Chad M. Robins
Headquarters
1165 Eastlake Avenue East, Seattle, WA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Chad M. Robins
Headquarters
1165 Eastlake Avenue East, Seattle, WA, US
Description

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.

The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection.

It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines.

In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications.

Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test.

The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Adaptive Biotechnologies Corporation. Starting points for Adaptive Biotechnologies Corporation: EPS -$0.44, beta 2.15 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Adaptive Biotechnologies Corporation. Trailing twelve-month EPS for Adaptive Biotechnologies Corporation stands at -$0.44. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
Analysts' target$31.58average of 6 firms, last 12 months
Current price—

Buy

Targets, low to high

$31.58

Low $27.00

Middle $33.00

High $35.00

Analyst ratings

6 firms, last 12 months
  • Strong Buy0
  • Buy5
  • Hold1
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.03−$0.06−$0.39−$0.07
Lowest estimate−$0.04−$0.08−$0.40−$0.11
Highest estimate−$0.03−$0.05−$0.37$0.05
Number of analysts3344
A year ago−$0.091−$0.13−$0.391—
Growth vs a year ago—+50.5%——

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$80.55M$80.56M$307.00M$374.36M
Lowest estimate$79.23M$79.62M$305.73M$370.51M
Highest estimate$82.76M$82.31M$309.20M$381.03M
Number of analysts6566
A year ago$71.68M$70.87M$276.98M—
Growth vs a year ago+12.4%+13.7%+10.8%—
Recent rating and target changes (15)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Adaptive Biotechnologies Corporation. Adaptive Biotechnologies Corporation has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ADPT12 companies · 8 funds
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
ELTXElicio Therapeutics, Inc.HealthcareNASDAQ$30.3M
ELUTElutia Inc.HealthcareNASDAQ$36.8M
ELVNEnliven Therapeutics, Inc.HealthcareNASDAQ$3.3B
EMMAEmmaus Life Sciences, Inc.HealthcareOTC$894,118
ENDVEndonovo Therapeutics, Inc.HealthcareOTC$31,875
ENGNenGene Holdings Inc.HealthcareNASDAQ$124.0M
ENGNWenGene Holdings Inc. WarrantsHealthcareNASDAQ$9.2M
ENLVEnlivex Therapeutics Ltd.HealthcareNASDAQ$20.2M
ENP.AXEntropy Neurodynamics LimitedHealthcareASX—
ENSCEnsysce Biosciences, Inc.HealthcareNASDAQ$7.2M
ENTAEnanta Pharmaceuticals, Inc.HealthcareNASDAQ$239.7M
ENTXEntera Bio Ltd.HealthcareNASDAQ$567.7M
ETFs holding Adaptive Biotechnologies Corporation
TickerFundFund assets% of the fund
IWMiShares Russell 2000 ETF$76.6B in assets0.16%
VTIVanguard Total Stock Market ETF$689.2B in assets0.01%
ARKGARK Genomic Revolution ETF$2.2B in assets2.88%
VBVanguard Small-Cap ETF$76.9B in assets0.02%
HELXFranklin Genomic Advancements ETF$33M in assets5.10%
HTECROBO Global Healthcare Technology and Innovation ETF$110M in assets2.05%
TMATMain Thematic Innovation ETF$212M in assets1.56%
DWASInvesco Dorsey Wright SmallCap Momentum ETF$376M in assets1.43%

Largest holders first, then the funds most concentrated in ADPT.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Adaptive Biotechnologies Corporation, and how their positions are changing. At a $4.61B market value, institutional positions materially move Adaptive Biotechnologies Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Adaptive Biotechnologies Corporation executives and directors. Shares of Adaptive Biotechnologies Corporation have traded between $4.27 and $17.89 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Adaptive Biotechnologies Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Adaptive Biotechnologies Corporation. Coverage tracks Adaptive Biotechnologies Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Adaptive Biotechnologies Corporation.

ADPT AnalysisGood
Past
5
Growth
5
Health
3
Profit
1
Value
1